Immediate Impact
61 standout
Citing Papers
GPCR drug discovery: new agents, targets and indications
2025 Standout
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
2025 Standout
Works of J. L. Steegmann being referenced
Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study
2015
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| J. L. Steegmann | 296 | 213 | 114 | 13 | 361 | |
| Karima Yacouben | 230 | 130 | 103 | 12 | 327 | |
| Silvia Bungaro | 205 | 118 | 69 | 12 | 319 | |
| Sara Vieira | 157 | 101 | 53 | 14 | 325 | |
| Pedro Enrique Dorlhiac Llacer | 284 | 249 | 163 | 9 | 318 | |
| Lucia Tornaghi | 234 | 165 | 119 | 11 | 330 | |
| Nadja Jaekel | 276 | 160 | 38 | 21 | 359 | |
| Mirna Golemović | 226 | 164 | 122 | 22 | 314 | |
| Matthias Klammer | 256 | 207 | 167 | 11 | 394 | |
| G Yoffe | 277 | 201 | 69 | 11 | 352 | |
| S Miyawaki | 211 | 95 | 69 | 8 | 329 |
All Works
Loading papers...